Navigation Links
Optigenex Inc. Signs New License and Distribution Agreement With Itochu Corporation of Japan
Date:4/6/2009

Company extends the term and expands territorial rights of its exclusive licensee in Japan after Itochu reaches market penetration milestone of 100 customer manufacturers in Japan for cosmeceutical and dietary supplement products using patented AC-11(R) (formerly known as C-Med- 100(R))

Increase in consumer demand fueled by results of new research showing that that orally administered AC-11(R) supplement increases the production of collagen III in the epidermis layer of the skin.

NEW YORK, April 6 /PRNewswire-FirstCall/ -- Optigenex Inc. (Pink Sheets: OPGX) announced today the signing of an extended and expanded new contract with its distribution partner in Asia (Itochu Corporation). Under the new license, Itochu has the right to market AC-11(R) technology exclusively in Japan and non-exclusively throughout the rest of Asia (Additional details were not disclosed). The new agreement represents the fulfillment of an important strategic objective to the company in terms of its business development plans for the Asia and further validates its business model in Japan and other countries in the region.

To date, Itochu has introduced AC-11(R) to over 100 companies in the cosmetic and dietary supplement market, with over 130 products containing AC-11(R) being marketed and sold. AC-11(R) is a patented, all-natural rain forest botanical extract that helps the body's natural ability to repair damage to its own DNA due to multiple causes, including harmful effects of UV radiation from over exposure to the sun, stress, environmental pollution and other toxins. In its standard bulk powder form, AC-11(R) supplement may be consumed orally or combined with liposomes and other delivery mechanisms for topical application on the skin.

The increase in demand for AC-11(R)-based products follows the issuance of a report in October 2008 by a leading French dermatological research center showing that orally administered AC-11(R) supplement increases the production of collagen III in the epidermis layer of the skin by stimulating expression of the COL3A1 gene. Collagen III is important for the development of skin and the cardiovascular system and for maintaining normal physiological functions in adult life. Results of the study suggest that oral and topical AC-11(R) products, when combined, are an inner and outer beauty solution to help reverse the signs of premature aging.

The French research, which was sponsored by Itochu, compliments earlier published third party studies demonstrating the effectiveness of AC-11(R) as a unique DNA repair adjuvant, as well as a natural inhibitor of pro-inflammatory agents and a natural immune system supporter.

Itochu partners with Optigenex under an Exclusive Supply and Trademark Licensing Agreement to market AC-11(R) bulk material and consumer products containing AC-11(R) under sublicenses in Japan and several other Asian countries.

Daniel Zwiren, president and CEO of Optigenex Inc. said, "We are excited by our new agreement with Itochu and equally with the results of the French laboratory study and by Itochu's joint commitment with us to expand the science behind AC-11(R). The personal care products market in Japan and the rest of Asia continues to grow. With Itochu's efforts, we are confident that Optigenex and AC-11(R) will be part of that growth."

Yusuke Itou of Itochu Corporation added the following, "We are very pleased with the positive reception AC-11(R) has received from manufacturers in Japan and our expanding role in marketing AC-11(R) in Southeast Asia. We anticipate strong demand for additional AC-11(R)-based products in the remainder of 2009 and beyond as consumer awareness of the benefits of AC-11(R) for healthy DNA maintenance and natural skin collagen production increases."

About ITOCHU Corporation:

Itochu Corporation is one of Japan's leading trading companies and is engaged in a wide variety of businesses, including food products, personal care products, textiles, technology multimedia, metals, energy, chemicals, forest products, retail and financial services. Itochu has approximately 45,690 employees maintains over 130 offices and owns over 651 subsidiaries and affiliates around the world. Itochu's sales last year reached 11.58 trillion yen (U.S. $95 billion.) (Update sales revenue and company figures)

About Optigenex Inc.:

Optigenex inc. is a formulator, distributor and provider of proprietary next generation skin care, supplements and bulk ingredient featuring AC-11(R) (Formerly known as C-MED-100(R)) a patented compound as it core product. AC- 11(R) is the bioactive, water soluble form of the medicinal herb Uncaria tomentosa. For more information about Optigenex please email the company at: dzwiren@optigenex.com


'/>"/>
SOURCE Optigenex Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
2. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
3. Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
4. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
5. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
6. Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials
7. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
8. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
9. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Kan. , Dec. 7, 2016   Rx Savings ... West Virginia and its Public Employees Insurance Agency ... members access to their innovative healthcare software, ultimately saving money ... with PEIA and provide its members with access to our ... or a more effective, affordable therapy can be found," says ...
(Date:12/7/2016)... Dec. 7, 2016  Varian Medical Systems (NYSE: ... previously announced plans to separate its Imaging Components business.  ... tax-free distribution to Varian stockholders of common stock in ... will hold the Imaging Components business.  As part of ... by the end of January 2017, Varian will receive ...
(Date:12/7/2016)... 7,2016  Based on its recent analysis ... & Sullivan recognizes Nemaura Pharma Limited with ... for Enabling Technology Leadership. Nemaura Pharma,s transdermal ... traditional drug delivery technologies, especially in delivering ... delivery technologies, Memspatch and Micropatch respectively, facilitate ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, a ... throughout the Five Boroughs, is launching a charity drive to raise funds that will ... traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the MCL, ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John ... by donating a portion of proceeds to two local organizations: North Chicago Animal Control ... & Friends is a team of authorized and trained volunteers who support rescued ...
(Date:12/7/2016)... ... ... The medical profession is well aware that heart attacks do indeed increase ... attacks among 138,602 people recorded a 35% higher number of heart attacks in December ... course–no time of year is a good time for a heart attack! In the ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... (IFW) Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 ... of three acupuncturists to help patients realize their family building goals. Acupuncture ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Fred Rides a Train” allows readers to ... , “Fred Rides a Train” is the creation of published author, Janet Morrison, ... teen years in Michigan. The "Fred, the Dog" series is her first attempt at ...
Breaking Medicine News(10 mins):